2025
Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles.
Liu Y, Wang X, Krishnan N, Hsiao T, Ji Y, Kaneko K, Teneche M, Adams P, Zuniga E, Kaech S, Zhang L, Feng G. Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles. Hepatology 2025 PMID: 40928035, DOI: 10.1097/hep.0000000000001514.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAPD-L1Liver tumorsLipid nanoparticlesTumor-suppressive effectsSingle doseCD8+ T cell infiltrationAnti-PD-L1 antibodyLiver cancerAssociated with several adverse effectsAnti-PD-L1T cell infiltrationMetastatic liver tumorsMechanism-based therapeutic agentsHepatic immune microenvironmentType I Interferon SignalingLiver tumor modelLiver tumor progressionLiver-targeting strategiesSevere adverse effectsI interferon signalingEfficacious monotherapyCheckpoint inhibitorsAntitumor immunityAntitumor responseAdaptation to Volumetric Compression Drives an Apoptosis-Resistant and Invasive Phenotype in Liver Cancer.
Gong X, Ogino N, Leite M, Zhang D, Chen Z, Nguyen R, Liu R, Kruglov E, Flores K, Cabral A, Moreira de M Mendes G, Ehrlich B, Mak M. Adaptation to Volumetric Compression Drives an Apoptosis-Resistant and Invasive Phenotype in Liver Cancer. Cancer Research 2025, 85: 3156-3175. PMID: 40387600, PMCID: PMC12354003, DOI: 10.1158/0008-5472.can-24-0859.Peer-Reviewed Original ResearchEpithelial-to-mesenchymal transition genesLiver cancerResistance to apoptosisCell state transitionsProliferation of tumor cellsYAP nuclear translocationCancer cell invasionIntracellular calcium signalingLiver cancer developmentTranscriptional dynamicsRac1 activationCellular protrusionsInhibiting Rac1Apoptosis-resistantTranscriptional changesInvasive phenotypeIntracellular calciumTumor cellsCell invasionNuclear translocationCancer developmentCalcium signalingTransition genesCancer cellsLiver-specific markersCancer Mortality
Hjartåker A, Weiderpass E, Bray F. Cancer Mortality. 2025, 171-182. DOI: 10.1016/b978-0-323-99967-0.00162-9.Peer-Reviewed Original ResearchCancer mortality burdenMortality burdenCancer mortality trendsGlobal cancer controlCancer deathCancer mortality dataHigher-income settingsProportion of deathsMortality trendsMortality dataCause of cancer deathCancer controlColorectal cancerMiddle-income economiesMeasure of progressLiver cancerCancer formsMortality rateColorectalBurdenData sourcesWorld regionsCancerDeathFrequent cause
2024
Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer
Xia Y, Zhou J, Xun X, Johnston L, Wei T, Gao R, Zhang Y, Reddy B, Liu C, Kim G, Zhang J, Zhao S, Yu Z. Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer. Npj Precision Oncology 2024, 8: 263. PMID: 39551847, PMCID: PMC11570623, DOI: 10.1038/s41698-024-00754-z.Peer-Reviewed Original ResearchProgression-free survivalCT scanLiver cancerAccurate treatment response assessmentResponse evaluationMetastatic organ sitesOncological treatment outcomesResponse Evaluation CriteriaLow-risk patientsTreatment response assessmentTreatment response evaluationTreatment response classificationAdvanced liver cancerStratify high-riskMultifocal hepatic lesionsTreatment outcome assessmentEvaluation of responseOverall survivalEvaluation CriteriaInternal five-fold cross-validationOncology clinical trialsResponse assessmentSolid tumorsClinical trialsTreatment outcomesDiabetes risk reduction diet and risk of liver cancer and chronic liver disease mortality: A prospective cohort study
Chen Y, Zhao L, Jung S, Pichardo M, Lopez‐Pentecost M, Rohan T, Saquib N, Sun Y, Tabung F, Zheng T, Wactawski‐Wende J, Manson J, Neuhouser M, Zhang X. Diabetes risk reduction diet and risk of liver cancer and chronic liver disease mortality: A prospective cohort study. Journal Of Internal Medicine 2024, 296: 410-421. PMID: 39239793, PMCID: PMC12161121, DOI: 10.1111/joim.20007.Peer-Reviewed Original ResearchChronic liver disease mortalityDiabetes risk reduction dietLiver disease mortalitySugar-sweetened beveragesDRRD scoreFood-frequency questionnaireDisease mortalityFood-frequencyIncident liver cancer casesChronic liver disease deathsWomen's Health Initiative-Observational StudyHazard ratioRisk of liver cancerLiver disease deathsTrans fatConfidence intervalsMultivariable hazard ratiosAssociated with reduced riskLiver cancer incidencePostmenopausal womenLiver cancerIntake of dietary fiberCox proportional hazards regression modelsProspective cohort studyRisk of liver cancer developmentUltra-processed products and risk of liver cancer: A prospective cohort study
Zhao L, Zhang X, Yu D, Wang L, Shrubsole M, Zheng W, Sudenga S, Zhang X. Ultra-processed products and risk of liver cancer: A prospective cohort study. Clinical Nutrition 2024, 43: 2298-2304. PMID: 39226717, PMCID: PMC11479389, DOI: 10.1016/j.clnu.2024.08.011.Peer-Reviewed Original ResearchConceptsUltra-processed foodsRisk of liver cancerUltra-processed productsLiver cancer riskCancer riskAssociated with liver cancer riskIntake of ultra-processed foodsIncident liver cancer casesSouthern Community Cohort StudyHigher risk of liver cancerCohort studyYear Follow-UpElevated risk of liver cancerElevated riskIncident liver cancerState Cancer RegistryNational Death IndexCommunity Cohort StudyFood frequency questionnaireLiver cancerProspective cohort studyHigh riskLiver cancer casesNOVA classificationCancer RegistryDiabetes Risk Reduction Diet and Risk of Liver Cancer and Chronic Liver Disease Mortality: A Prospective Cohort Study
Chen Y, Zhao L, Jung S, Pichardo M, Lopez-Pentecost M, Rohan T, Saquib N, Sun Y, Tabung F, Zheng T, Wactawski-Wende J, Manson J, Neuhouser M, Zhang X. Diabetes Risk Reduction Diet and Risk of Liver Cancer and Chronic Liver Disease Mortality: A Prospective Cohort Study. Current Developments In Nutrition 2024, 8: 102547. DOI: 10.1016/j.cdnut.2024.102547.Peer-Reviewed Original ResearchDeep Learning-Based Detect-Then-Track Pipeline for Treatment Outcome Assessments in Immunotherapy-Treated Liver Cancer
Zhou J, Xia Y, Xun X, Yu Z. Deep Learning-Based Detect-Then-Track Pipeline for Treatment Outcome Assessments in Immunotherapy-Treated Liver Cancer. Journal Of Imaging Informatics In Medicine 2024, 38: 380-393. PMID: 38740661, PMCID: PMC11811366, DOI: 10.1007/s10278-024-01132-8.Peer-Reviewed Original ResearchArtificial intelligence in liver cancer — new tools for research and patient management
Calderaro J, Žigutytė L, Truhn D, Jaffe A, Kather J. Artificial intelligence in liver cancer — new tools for research and patient management. Nature Reviews Gastroenterology & Hepatology 2024, 21: 585-599. PMID: 38627537, DOI: 10.1038/s41575-024-00919-y.Peer-Reviewed Original ResearchLiver cancer managementLiver cancerCancer managementCancer careArtificial intelligenceClinically approved productsInterdisciplinary trainingTumor typesClinical dataClinical trialsPatient managementClinical useCancerPotential of AILiverHidden informationNatural languageIncorporation of AIAI approachesAI systemsPatients
2023
Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Vylegzhanina A, Bespalov I, Novototskaya-Vlasova K, Hall B, Gleiberman A, Yu H, Leontieva O, Leonova K, Kurnasov O, Osterman A, Dy G, Komissarov A, Vasilieva E, Gehlhausen J, Iwasaki A, Ambrosone C, Tsuji T, Matsuzaki J, Odunsi K, Andrianova E, Gudkov A. Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans. Cancer Research Communications 2023, 3: 2256-2267. PMID: 37870410, PMCID: PMC10631453, DOI: 10.1158/2767-9764.crc-23-0289.Peer-Reviewed Original ResearchConceptsL1 antigenCancer typesDisease stage 1Discovery of autoantibodiesHigh IgG titersTumor-associated antigensDetermination of immunoreactivityTumor immunoreactivityCirculating AntibodiesIgG titersAntibody responseImmune responseLiver cancerReactive IgGHealthy individualsCurable cancer typesImmune systemAntigenNormal tissuesPatientsCancerEarly detectionElevated levelsCarcinogenic processAutoantibodiesScreening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosisAmbient fine particulate matter exposure and risk of incident liver cancer in the NIH-AARP Diet and Health Study
Ma X, Fisher J, McGlynn K, Liao L, Vasiliou V, Sun N, Kaufman J, Silverman D, Jones R. Ambient fine particulate matter exposure and risk of incident liver cancer in the NIH-AARP Diet and Health Study. ISEE Conference Abstracts 2023, 2023 DOI: 10.1289/isee.2023.vo-011.Peer-Reviewed Original ResearchConsensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management
Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang T, Knobloch G, Koh D, Kudo M, Lee J, Murakami T, Pinato D, Ringe K, Song B, Tabrizian P, Wang J, Yoon J, Zeng M, Zhou J, Vilgrain V. Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management. European Radiology 2023, 33: 9152-9166. PMID: 37500964, PMCID: PMC10730664, DOI: 10.1007/s00330-023-09928-y.Peer-Reviewed Original ResearchConceptsGadoxetic acid-enhanced magnetic resonance imagingLiver magnetic resonance imagingMagnetic resonance imagingHCC managementResonance imagingOutcome of HCCScreening/surveillanceLiver cancer screeningPrediction of prognosisWestern guidelinesCancer screeningLiver surgeonsLiver surgeryConsensus statementHCC screeningTreatment responseConsensus reportLiver cancerInterventional radiologistsClinical relevanceClinical practiceGadoxetic acidEmerging DataHCCDiagnosisDaytime napping, nighttime sleeping duration, and risk of hepatocellular carcinoma and liver disease-related mortality
Long L, Zhao L, Petrick J, Liao L, Huang T, Hakim A, Yang W, Campbell P, Giovannucci E, McGlynn K, Zhang X. Daytime napping, nighttime sleeping duration, and risk of hepatocellular carcinoma and liver disease-related mortality. JHEP Reports 2023, 5: 100819. PMID: 37691690, PMCID: PMC10482745, DOI: 10.1016/j.jhepr.2023.100819.Peer-Reviewed Original ResearchChronic liver disease mortalityNational Institutes of Health-American Association of Retired PersonsRisk of hepatocellular carcinomaChronic liver disease deathsAssociations of nighttime sleep durationChronic liver diseaseAssociated with higher risk of hepatocellular carcinomaClinical follow-up of individualsHigh risk of hepatocellular carcinomaNighttime sleep durationDaytime napping durationClinical follow-upNap durationAssociated with higher riskHepatocellular carcinomaLiver diseaseSleep durationDevelopment of liver cancerLiver cancerCalculate multivariable hazard ratiosAssociation of Retired PersonsHazard ratioLonger daytime napping durationMedian follow-up timeIncidence of hepatocellular carcinomaA Treg-specific long noncoding RNA maintains immune-metabolic homeostasis in aging liver
Ding C, Yu Z, Sefik E, Zhou J, Kaffe E, Wang G, Li B, Flavell R, Hu W, Ye Y, Li H. A Treg-specific long noncoding RNA maintains immune-metabolic homeostasis in aging liver. Nature Aging 2023, 3: 813-828. PMID: 37277640, DOI: 10.1038/s43587-023-00428-8.Peer-Reviewed Original ResearchConceptsAged miceLiver diseaseLiver microenvironmentAge-related liver diseasesYin Yang 1Liver immune microenvironmentRegulatory T cellsTreg-specific deletionPotential therapeutic targetMitochondrial functionYang 1Treg apoptosisTreg homeostasisTreg cellsTreg functionImmune microenvironmentLiver fibrosisMetabolic dysfunctionOptimal mitochondrial functionYoung miceT cellsLiver cancerTherapeutic targetAged liverLong noncoding RNALiver cancer risk quantification through an artificial neural network based on personal health data
Ataei A, Deng J, Muhammad W. Liver cancer risk quantification through an artificial neural network based on personal health data. Acta Oncologica 2023, 62: 495-502. PMID: 37211681, DOI: 10.1080/0284186x.2023.2213445.Peer-Reviewed Original ResearchConceptsNational Health Interview SurveyLiver cancer riskHealth dataCancer riskHealth Interview SurveyHepatocellular carcinomaPersonal health dataHigh-risk populationLiver cancerInterview SurveyReceiver operating characteristic curveArea under the receiver operating characteristic curveCancer-related deathsPrimary liver cancerHealthOvarian cancerTherapeutic optionsMalignant diseaseTest cohortEarly detectionAggressive progressionRiskCancerCharacteristic curveLiverLI-RADS: Looking Back, Looking Forward.
Chernyak V, Fowler K, Do R, Kamaya A, Kono Y, Tang A, Mitchell D, Weinreb J, Santillan C, Sirlin C. LI-RADS: Looking Back, Looking Forward. Radiology 2023, 307: e222801. PMID: 36853182, PMCID: PMC10068888, DOI: 10.1148/radiol.222801.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaLI-RADSSensitivity of LR-5Imaging modalitiesRadiation-based therapyTreatment response assessmentLiver Imaging ReportingLiver imaging modalityQuantitative imaging featuresExtracellular contrast agentsContrast agentsLR-5Systemic treatmentResponse assessmentImaging ReportingPatient characteristicsLiver cancerIndeterminate observationsClinical careDiagnosisLiverModalitiesReporting templateTreatmentImage featuresGlobal burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences, 1990-2019: a DALYs-based analysis of the Global Burden of Disease 2019 study
Choi S, Kim B, Yon D, Lee S, Lee H, Chang H, Park S, Koyanagi A, Jacob L, Dragioti E, Radua J, Shin J, Kim S, Smith L. Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences, 1990-2019: a DALYs-based analysis of the Global Burden of Disease 2019 study. Clinical And Molecular Hepatology 2023, 29: 433-452. PMID: 36597018, PMCID: PMC10121317, DOI: 10.3350/cmh.2022.0316.Peer-Reviewed Original ResearchConceptsDisease-adjusted life yearsGlobal burdenAlcohol consumptionSociodemographic statusCancer aetiologyBurden of primary liver cancerMortality rates of liver cancerGlobal Burden of DiseaseHigh-income Asia-Pacific regionRate of liver cancerAge-standardized DALY rateGlobal Burden of Disease 2019 studyMortality rateHigh-income Asia PacificBurden of diseaseStudy periodHepatitis B virusHepatitis C virusDALY ratesSociodemographic indexCrude numberLife yearsHigher incomeLiver cancerCentral Asia populationsDisparities in stage at diagnosis for liver cancer in China
Shan T, Ran X, Li H, Feng G, Zhang S, Zhang X, Zhang L, Lu L, An L, Fu R, Sun K, Wang S, Chen R, Li L, Chen W, Wei W, Zeng H, He J. Disparities in stage at diagnosis for liver cancer in China. Journal Of The National Cancer Center 2023, 3: 7-13. PMID: 39036312, PMCID: PMC11256694, DOI: 10.1016/j.jncc.2022.12.002.Peer-Reviewed Original ResearchLiver cancerStage IIIStage distributionHospital-based studyProportion of patientsLiver Cancer stagePrimary liver cancerCancer control policiesCancer awarenessCancer stageTreatment strategiesFamily historyStudy populationStage ISocioeconomic populationsCancerLogistic regressionPatientsDiagnosisEarly detectionHigher proportionDifferent populationsPopulationProportionHospitalMitochondrial calcium signaling in cholangiocarcinoma
Loyola-Machado A, Guerra M, Nathanson M. Mitochondrial calcium signaling in cholangiocarcinoma. Hepatoma Research 2023, 9: null-null. DOI: 10.20517/2394-5079.2023.28.Peer-Reviewed Original ResearchPrimary liver cancerNew pharmacological agentsPathogenesis of cholangiocarcinomaMitochondrial Ca2Liver cancerCholangiocarcinomaPharmacological agentsIntracellular Ca2Molecular alterationsDruggable targetsER-mitochondrial contact sitesCancer cellsKey regulatory moleculesMetabolic reprogramingReceptor familyMitochondrial healthMitochondrial calciumEnergy metabolismCell deathPathways of interestLatest findingsTreatmentCa2Regulatory moleculesContact sites
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply